MedTrace Logo

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

NCT03777124 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-07-04

No results posted yet for this study

Summary

This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer

Conditions

  • NSCLC Stage IV
  • KRAS Gene Mutation
  • PD-1 Antibody
  • Chemotherapy Effect

Interventions

DRUG

SHR-1210

Subjects receive SHR-1210 intravenous every 2 weeks

DRUG

Apatinib

Subjects receive Apatinib orally every day

DRUG

Pemetrexed

Subjects receive Pemetrexed intravenous every 3 weeks

DRUG

Carboplatin

subjects receive carboplatin intravenous every 3 weeks

Sponsors & Collaborators

  • Shanghai Chest Hospital

    collaborator OTHER

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianjun Zou, MD, PhD · Jiangsu HengRui Medicine Co., Ltd.

  • Shun Lu, MD, PhD · Jiaotong University,Shanghai chest Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-11
Primary Completion
2023-06-29
Completion
2023-06-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03777124 on ClinicalTrials.gov